Celcuity Inc. (NASDAQ:CELC) Position Increased by Pale Fire Capital SE

Pale Fire Capital SE raised its position in shares of Celcuity Inc. (NASDAQ:CELC) by 38.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,409 shares of the company’s stock after buying an additional 4,000 shares during the quarter. Pale Fire Capital SE’s holdings in Celcuity were worth $210,000 at the end of the most recent quarter.

Separately, SG Americas Securities LLC purchased a new stake in Celcuity during the fourth quarter valued at about $139,000. 63.33% of the stock is owned by institutional investors.

Celcuity Stock Down 0.4 %

Shares of CELC traded down $0.06 during trading hours on Friday, reaching $14.29. The company’s stock had a trading volume of 104,020 shares, compared to its average volume of 239,965. The firm has a market cap of $446.28 million, a price-to-earnings ratio of -5.14 and a beta of 0.85. Celcuity Inc. has a 1-year low of $8.39 and a 1-year high of $22.19. The company has a quick ratio of 11.23, a current ratio of 11.23 and a debt-to-equity ratio of 0.28. The company has a 50 day moving average of $17.05 and a two-hundred day moving average of $16.08.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, May 15th. The company reported ($0.64) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.07. As a group, research analysts predict that Celcuity Inc. will post -2.85 EPS for the current fiscal year.

Analyst Ratings Changes

CELC has been the subject of a number of analyst reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $40.00 price objective on shares of Celcuity in a research note on Thursday, May 16th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 price objective on shares of Celcuity in a research note on Thursday, May 16th. Craig Hallum reiterated a “buy” rating and issued a $27.00 target price (up previously from $25.00) on shares of Celcuity in a report on Thursday, May 16th. Finally, Needham & Company LLC dropped their target price on Celcuity from $24.00 to $23.00 and set a “buy” rating on the stock in a report on Friday, May 31st.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.